TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 174 filers reported holding TRAVERE THERAPEUTICS INC in Q1 2024. The put-call ratio across all filers is 3.96 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $7,972,512 | +6.8% | 969,892 | +0.2% | 1.07% | +16.6% |
| Q1 2024 | $7,466,518 | -18.5% | 968,420 | -4.9% | 0.92% | -29.0% |
| Q4 2023 | $9,159,120 | +77.4% | 1,018,812 | +76.4% | 1.29% | +36.4% |
| Q3 2023 | $5,162,796 | +129.7% | 577,494 | +294.7% | 0.95% | +142.6% |
| Q2 2023 | $2,247,521 | -29.6% | 146,323 | +3.1% | 0.39% | -43.8% |
| Q1 2023 | $3,191,039 | +564.5% | 141,887 | +521.4% | 0.69% | +442.2% |
| Q4 2022 | $480,220 | -26.7% | 22,835 | -14.0% | 0.13% | -31.2% |
| Q3 2022 | $655,000 | +3.0% | 26,565 | +1.2% | 0.19% | -20.5% |
| Q2 2022 | $636,000 | – | 26,250 | – | 0.23% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 1,026,300 | $21,583 | 6.98% |
| Deep Track Capital, LP | 4,582,000 | $96,359,460 | 4.05% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 379,019 | $7,963,189 | 2.46% |
| ARMISTICE CAPITAL, LLC | 6,412,000 | $134,844,360 | 2.35% |
| GREAT POINT PARTNERS LLC | 475,000 | $9,989,250 | 1.96% |
| RA Capital Management | 3,984,681 | $83,797,841 | 1.70% |
| MPM BioImpact LLC | 281,711 | $5,924,382 | 1.54% |
| HighVista Strategies LLC | 121,834 | $2,562,169 | 1.52% |
| Kynam Capital Management, LP | 418,099 | $8,792,622 | 1.35% |
| SECTORAL ASSET MANAGEMENT INC | 292,320 | $6,147,490 | 1.19% |